vs

Side-by-side financial comparison of AEHR TEST SYSTEMS (AEHR) and C4 Therapeutics, Inc. (CCCC). Click either name above to swap in a different company.

C4 Therapeutics, Inc. is the larger business by last-quarter revenue ($11.0M vs $9.9M, roughly 1.1× AEHR TEST SYSTEMS). AEHR TEST SYSTEMS runs the higher net margin — -32.7% vs -186.0%, a 153.3% gap on every dollar of revenue. On growth, C4 Therapeutics, Inc. posted the faster year-over-year revenue change (112.8% vs -26.5%). Over the past eight quarters, C4 Therapeutics, Inc.'s revenue compounded faster (90.4% CAGR vs 14.3%).

Aehr Test Systems designs, manufactures and sells advanced test and burn-in systems for the global semiconductor industry. Its products help semiconductor manufacturers, packaging firms and chip designers validate reliability of logic, memory and power semiconductor devices, serving markets across North America, Asia and Europe.

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies for cancer and other severe diseases with high unmet medical needs. It leverages its proprietary TORPEDO platform to design small molecule degraders that eliminate disease-causing proteins, with a pipeline of oncology candidates in preclinical and clinical development, plus strategic partnerships with leading global pharmaceutical firms.

AEHR vs CCCC — Head-to-Head

Bigger by revenue
CCCC
CCCC
1.1× larger
CCCC
$11.0M
$9.9M
AEHR
Growing faster (revenue YoY)
CCCC
CCCC
+139.3% gap
CCCC
112.8%
-26.5%
AEHR
Higher net margin
AEHR
AEHR
153.3% more per $
AEHR
-32.7%
-186.0%
CCCC
Faster 2-yr revenue CAGR
CCCC
CCCC
Annualised
CCCC
90.4%
14.3%
AEHR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AEHR
AEHR
CCCC
CCCC
Revenue
$9.9M
$11.0M
Net Profit
$-3.2M
$-20.5M
Gross Margin
25.7%
Operating Margin
-47.0%
-210.1%
Net Margin
-32.7%
-186.0%
Revenue YoY
-26.5%
112.8%
Net Profit YoY
-214.2%
40.7%
EPS (diluted)
$-0.11
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AEHR
AEHR
CCCC
CCCC
Q4 25
$9.9M
$11.0M
Q3 25
$11.0M
$11.2M
Q2 25
$14.1M
$6.5M
Q1 25
$18.3M
$7.2M
Q4 24
$13.5M
$5.2M
Q3 24
$13.1M
$15.4M
Q2 24
$16.6M
$12.0M
Q1 24
$7.6M
$3.0M
Net Profit
AEHR
AEHR
CCCC
CCCC
Q4 25
$-3.2M
$-20.5M
Q3 25
$-2.1M
$-32.2M
Q2 25
$-2.9M
$-26.0M
Q1 25
$-643.0K
$-26.3M
Q4 24
$-1.0M
$-34.6M
Q3 24
$660.0K
$-24.7M
Q2 24
$23.9M
$-17.7M
Q1 24
$-1.5M
$-28.4M
Gross Margin
AEHR
AEHR
CCCC
CCCC
Q4 25
25.7%
Q3 25
33.9%
Q2 25
30.3%
Q1 25
39.2%
Q4 24
40.1%
Q3 24
54.0%
Q2 24
50.9%
Q1 24
41.7%
Operating Margin
AEHR
AEHR
CCCC
CCCC
Q4 25
-47.0%
-210.1%
Q3 25
-37.1%
-306.4%
Q2 25
-22.7%
-441.0%
Q1 25
-6.1%
-402.9%
Q4 24
-11.2%
-728.4%
Q3 24
1.2%
-183.9%
Q2 24
15.3%
-178.6%
Q1 24
-27.1%
-1060.2%
Net Margin
AEHR
AEHR
CCCC
CCCC
Q4 25
-32.7%
-186.0%
Q3 25
-19.0%
-286.4%
Q2 25
-20.6%
-402.6%
Q1 25
-3.5%
-363.7%
Q4 24
-7.6%
-667.8%
Q3 24
5.0%
-160.6%
Q2 24
143.8%
-147.6%
Q1 24
-19.4%
-933.2%
EPS (diluted)
AEHR
AEHR
CCCC
CCCC
Q4 25
$-0.11
$-0.09
Q3 25
$-0.07
$-0.44
Q2 25
$-0.10
$-0.37
Q1 25
$-0.02
$-0.37
Q4 24
$-0.03
$-0.50
Q3 24
$0.02
$-0.35
Q2 24
$0.81
$-0.26
Q1 24
$-0.05
$-0.41

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AEHR
AEHR
CCCC
CCCC
Cash + ST InvestmentsLiquidity on hand
$30.8M
$74.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$130.8M
$256.6M
Total Assets
$148.7M
$359.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AEHR
AEHR
CCCC
CCCC
Q4 25
$30.8M
$74.6M
Q3 25
$22.7M
$58.8M
Q2 25
$24.5M
$78.2M
Q1 25
$29.4M
$51.3M
Q4 24
$32.2M
$55.5M
Q3 24
$37.8M
$59.6M
Q2 24
$49.2M
$73.1M
Q1 24
$47.6M
$89.7M
Stockholders' Equity
AEHR
AEHR
CCCC
CCCC
Q4 25
$130.8M
$256.6M
Q3 25
$122.4M
$154.4M
Q2 25
$122.9M
$174.1M
Q1 25
$124.2M
$195.1M
Q4 24
$123.2M
$216.0M
Q3 24
$122.5M
$242.7M
Q2 24
$111.6M
$247.1M
Q1 24
$86.5M
$258.3M
Total Assets
AEHR
AEHR
CCCC
CCCC
Q4 25
$148.7M
$359.1M
Q3 25
$144.1M
$265.5M
Q2 25
$148.5M
$296.5M
Q1 25
$145.6M
$319.5M
Q4 24
$142.3M
$349.6M
Q3 24
$145.9M
$376.1M
Q2 24
$127.9M
$381.1M
Q1 24
$101.6M
$398.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AEHR
AEHR
CCCC
CCCC
Operating Cash FlowLast quarter
$-1.2M
$-22.1M
Free Cash FlowOCF − Capex
$-1.6M
FCF MarginFCF / Revenue
-16.6%
Capex IntensityCapex / Revenue
4.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-11.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AEHR
AEHR
CCCC
CCCC
Q4 25
$-1.2M
$-22.1M
Q3 25
$-282.0K
$-31.2M
Q2 25
$-2.3M
$-12.1M
Q1 25
$-1.6M
$-33.3M
Q4 24
$-5.9M
$-17.9M
Q3 24
$2.4M
$-24.1M
Q2 24
$1.2M
$-5.0M
Q1 24
$-2.8M
$-18.1M
Free Cash Flow
AEHR
AEHR
CCCC
CCCC
Q4 25
$-1.6M
Q3 25
$-1.7M
$-31.6M
Q2 25
$-5.1M
Q1 25
$-3.3M
Q4 24
$-6.2M
$-17.9M
Q3 24
$2.2M
$-24.1M
Q2 24
$1.2M
$-5.2M
Q1 24
$-3.1M
FCF Margin
AEHR
AEHR
CCCC
CCCC
Q4 25
-16.6%
Q3 25
-15.3%
-281.5%
Q2 25
-36.3%
Q1 25
-17.8%
Q4 24
-46.0%
-346.5%
Q3 24
16.6%
-157.2%
Q2 24
7.1%
-43.1%
Q1 24
-40.8%
Capex Intensity
AEHR
AEHR
CCCC
CCCC
Q4 25
4.7%
Q3 25
12.7%
3.7%
Q2 25
20.0%
Q1 25
9.0%
Q4 24
2.4%
0.1%
Q3 24
1.5%
0.1%
Q2 24
0.3%
1.6%
Q1 24
3.5%
0.0%
Cash Conversion
AEHR
AEHR
CCCC
CCCC
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
3.61×
Q2 24
0.05×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AEHR
AEHR

Systems$5.0M50%
Contactors$3.4M35%
Services$1.5M15%

CCCC
CCCC

Segment breakdown not available.

Related Comparisons